MUVON Therapeutics nominated as finalist for 2023 ZKB Pionierpreis
MUVON's team is very proud to be amongst the 12 finalists for the ZKB Pionierpreis in 2023! The recognition of the impact of our mission...
MUVON Therapeutics nominated as finalist for 2023 ZKB Pionierpreis
The leadership from MUVON Therapeutics AG will be attending JP Morgan Healthcare week in Jan 2023
MUVON Therapeutics announces appointments to its Board of Directors and Scientific Advisory Board
Muvon Therapeutics Announces First Patient Enrolled in Phase II Clinical Study
CEO Deana Mohr honored to present MUVON to Prof. Shinya Yamanaka, godfather of iPSCs
Muvon Therapeutics Announces Successful Phase I Clinical Study in Female Patients with SUI
Joint statement by the leading patient group WFIPP and MUVON Therapeutics AG
MUVON Therapeutics is supported by the Lichtsteiner Foundation
MUVON's CEO Deana Mohr featured in Top 30 In Vivo's Rising Leaders 2022
CEO Deana Mohr presented MUVON in interview for BioInnovation Spotlight
Translation and automation hurdles for cell therapies
MUVON wins second place at IFAS Innovation Challenge 2021
Deana Mohr wins spot in Venture Leaders Medtech 2021
MUVON featured by Startupticker
MUVON Therapeutics selected as finalist for the 2021 >>venture>> Startup Competition
MUVON Therapeutics selected for Tech4Eva accelerator program
Greater Zurich Area features MUVON Therapeutics in article on successful biotech innovations
MUVON is being accelerated by Wyss Zurich
Modern Therapy of Urinary Incontinence Using Muscle Stem Cells (Article in German)
The Beginning of the MUVON Story